ACS Medicinal Chemistry Letters
Letter
pyrrolidine derivatives as novel androgen receptor antagonists. Bioorg.
Med. Chem. 2013, 21, 70−83.
ACKNOWLEDGMENTS
■
This research was supported by the Department of Urology,
University of Pittsburgh and the Johnson & Johnson Corporate
Office of Science and Technology (COSAT) − University of
Pittsburgh Translational Innovation Partnership Program. The
authors thank Ms. Taber Lewis (University of Pittsburgh) for
LCMS analyses, Dr. Marianne Sadar (University of British
Columbia) for the PSA6.1--luc plasmid, and Dr. Leland W. K.
Chung (Cedars-Sinai Medical Center) for the C4-2 cell line.
(17) Balog, A.; Rampulla, R.; Martin, G. S.; Krystek, S. R.; Attar, R.;
Dell-John, J.; Dimarco, J. D.; Fairfax, D.; Gougoutas, J.; Holst, C. L.;
Nation, A.; Rizzo, C.; Rossiter, L. M.; Schweizer, L.; Shan, W.; Spergel,
S.; Spires, T.; Cornelius, G.; Gottardis, M.; Trainor, G.; Vite, G. D.;
Salvati, M. E. Discovery of BMS-641988, a novel androgen receptor
antagonist for the treatment of prostate cancer. ACS Med. Chem. Lett.
2015, 6, 908−912.
(18) Bradbury, R. H.; Acton, D. G.; Broadbent, N. L.; Brooks, A. N.;
Carr, G. R.; Hatter, G.; Hayter, B. R.; Hill, K. J.; Howe, N. J.; Jones, R.
D. O.; Jude, D.; Lamont, S. G.; Loddick, S. A.; Mcfarland, H. L.;
Parveen, Z.; Rabow, A. A.; Sharma-Singh, G.; Stratton, N. C.;
Thomason, A. G.; Trueman, D.; Walker, G. E.; Wells, S. L.; Wilson, J.;
Wood, J. M. Discovery of AZD3514, a small-molecule androgen
receptor downregulator for treatment of advanced prostate cancer.
Bioorg. Med. Chem. Lett. 2013, 23, 1945−1948.
(19) Guerrini, A.; Tesei, A.; Ferroni, C.; Paganelli, G.; Zamagni, A.;
Carloni, S.; Di Donato, M.; Castoria, G.; Leonetti, C.; Porru, M.; De
Cesare, M.; Zaffaroni, N.; Beretta, G. L.; Del Rio, A.; Varchi, G. A new
avenue toward androgen receptor pan-antagonists: C2 Sterically
hindered substitution of hydroxypropanamides. J. Med. Chem. 2014,
57, 7263−7279.
ABBREVIATIONS
■
AR, androgen receptor; 3,5-DMI, 3,5-dimethylisoxazole;
CRPC, castration-resistant prostate cancer; HTS, high-
throughput screen; MW, molecular weight; PSA, prostate-
specific antigen; SAR, structure−activity relationship; SD,
standard deviation
REFERENCES
■
(1) Bruchovsky, N.; Wilson, J. D. Discovery of the role of
dihydrotestosterone in androgen action. Steroids 1999, 64, 753−759.
(2) Huggins, C.; Hodges, C. V. Studies on prostatic cancer. I. The
effect of castration, of estrogen and of androgen injection on serum
phosphatases in metastatic carcinoma of the prostate. Cancer Res.
1941, 1, 293−297.
(20) Njar, V. C. O.; Brodie, A. M. H. Discovery and development of
galeterone (TOK-001 or VN/124−1) for the treatment of all stages of
prostate cancer. J. Med. Chem. 2015, 58, 2077−2087.
(21) Clegg, N. J.; Wongvipat, J.; Joseph, J. D.; Tran, C.; Ouk, S.;
Dilhas, A.; Chen, Y.; Grillot, K.; Bischoff, E. D.; Cai, L.; Aparicio, A.;
Dorow, S.; Arora, V.; Shao, G.; Qian, J.; Zhao, H.; Yang, G.; Cao, C.;
Sensintaffar, J.; Wasielewska, T.; Herbert, M. R.; Bonnefous, C.;
Darimont, B.; Scher, H. I.; Smith-Jones, P.; Klang, M.; Smith, N. D.;
De Stanchina, E.; Wu, N.; Ouerfelli, O.; Rix, P. J.; Heyman, R. A.; Jung,
M. E.; Sawyers, C. L.; Hager, J. H. ARN-509: A novel antiandrogen for
prostate cancer treatment. Cancer Res. 2012, 72, 1494−1503.
(22) Moilanen, A.-M.; Riikonen, R.; Oksala, R.; Ravanti, L.; Aho, E.;
Wohlfahrt, G.; Nykanen, P. S.; Tormakangas, O. P.; Kallio, P. J.;
Palvimo, J. J. Discovery of ODM-201, a new-generation androgen
receptor inhibitor targeting resistance mechanisms to androgen
signaling-directed prostate cancer therapies. Sci. Rep. 2015, 5, 12007.
(23) Johnston, P. A.; Nguyen, M. M.; Dar, J. A.; Ai, J.; Wang, Y.;
Masoodi, K. Z.; Shun, T.; Shinde, S.; Camaro, D. P.; Hua, Y.; Huryn,
D. M.; Wilson, G. M.; Lazo, J. S.; Nelson, J. B.; Wipf, P.; Wang, Z.
Development and implementation of a high-throughput high-content
screening assay to identify inhibitors of androgen receptor nuclear
localization in castration-resistant prostate cancer cells. Assay Drug Dev.
Technol. 2016, 14, 226−239.
(24) Demchenko, A. M.; Sinchenko, V. G.; Prodanchuk, N. G.;
Kovtunenko, V. A.; Patratii, V. K.; Tyltin, A. K.; Babichev, F. S.
Synthesis and antimycotic activity of 3-aryl-6,7-dihydro-5H-pyrrolo-
[1,2-a]imidazoles. Pharm. Chem. J. 1987, 21, 789−791.
(25) Vishwanatha, T. M.; Panguluri, N. R.; Sureshbabu, V. V.
Propanephosphonic acid anhydride (T3P)A benign reagent for
diverse applications inclusive of large-scale synthesis. Synthesis 2013,
45, 1569−1601.
(3) Linja, M. J.; Visakorpi, T. Alterations of androgen receptor in
prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92, 255−264.
(4) Zong, Y.; Goldstein, A. S. Adaptation or selection-mechanisms of
castration-resistant prostate cancer. Nat. Rev. Urol. 2013, 10, 90−98.
(5) Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. Ca-
Cancer J. Clin. 2014, 64, 9−29.
(7) Waltering, K. K.; Urbanucci, A.; Visakorpi, T. Androgen receptor
(AR) aberrations in castration-resistant prostate cancer. Mol. Cell.
Endocrinol. 2012, 360, 38−43.
(8) Haendler, B.; Cleve, A. Recent developments in antiandrogens
and selective androgen receptor modulators. Mol. Cell. Endocrinol.
2012, 352, 79−91.
(9) Chen, C. D.; Welsbie, D. S.; Tran, C.; Baek, S. H.; Chen, R.;
Vessella, R.; Rosenfeld, M. G.; Sawyers, C. L. Molecular determinants
of resistance to antiandrogen therapy. Nat. Med. 2004, 10, 33−39.
(10) Zegarra-Moro, O. L.; Schmidt, L. J.; Huang, H.; Tindall, D. J.
Disruption of androgen receptor function inhibits proliferation of
androgen-refractory prostate cancer cells. Cancer Res. 2002, 62, 1008−
1013.
(11) Gregory, C. W.; Johnson, R. T.; Mohler, J. L.; French, F. S.;
Wilson, E. M. Androgen receptor stabilization in recurrent prostate
cancer is associated with hypersensitivity to low androgen. Cancer Res.
2001, 61, 2892−2898.
(12) Rathkopf, D.; Scher, H. I. Androgen receptor antagonists in
castration-resistant prostate cancer. Cancer J. 2013, 19, 43−49.
(13) Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora,
V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.;
Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T.
M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development
of a second-generation antiandrogen for treatment of advanced
prostate cancer. Science 2009, 324, 787−790.
(14) Ciccarese, C.; Santoni, M.; Brunelli, M.; Buti, S.; Modena, A.;
Nabissi, M.; Artibani, W.; Martignoni, G.; Montironi, R.; Tortora, G.;
Massari, F. AR-V7 and prostate cancer: The watershed for treatment
selection? Cancer Treat. Rev. 2016, 43, 27−35.
(15) Ran, F.; Xing, H.; Liu, Y.; Zhang, D.; Li, P.; Zhao, G. Recent
developments in androgen receptor antagonists. Arch. Pharm. 2015,
348, 757−775.
(16) Yamamoto, S.; Kobayashi, H.; Kaku, T.; Aikawa, K.; Hara, T.;
Yamaoka, M.; Kanzaki, N.; Hasuoka, A.; Baba, A.; Ito, M. Design,
synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenyl-
(26) Cabello-Sanchez, N.; Jean, L.; Maddaluno, J.; Lasne, M.-C.;
Rouden, J. Palladium-mediated N-arylation of heterocyclic diamines:
insights into the origin of an unusual chemoselectivity. J. Org. Chem.
2007, 72, 2030−2039.
(27) Larsen, S. B.; Bang-Andersen, B.; Johansen, T. N.; Jørgensen, M.
Palladium-catalyzed monoamination of dihalogenated benzenes.
Tetrahedron 2008, 64, 2938−2950.
́ ́
(28) Concellon, J. M.; Rodríguez-Solla, H.; Mejica, C.; Blanco, E. G.
Stereospecific cyclopropanation of highly substituted C−C double
bonds promoted by CrCl2. Stereoselective synthesis of cyclo-
propanecarboxamides and cyclopropyl ketones. Org. Lett. 2007, 9,
2981−2984.
(29) Bogen, S. L.; Pan, W.; Ruan, S.; Chen, K. X.; Arasappan, A.;
Venkatraman, S.; Nair, L. G.; Sannigrahi, M.; Bennett, F. Inhibitors of
hepatitis C virus NS3 protease. WO 2005/085275.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX